HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Infectious Disease
RCT
Islatravir 60 mg oral qm showed 64.3% adverse event rate compared to 77.1% in comparator
Trial Shows Islatravir Shows Tolerable Safety Profile for HIV Prevention
This Phase 3 randomized trial evaluated islatravir 60 mg oral qm in 494 cisgender men and transgender women at increased risk of HIV-1 expos…
A Phase 3 trial of islatravir for HIV prevention showed the medication was generally well tolerated with fewer reported side effects than th…
Sep 11, 2026
Infectious Disease
RCT
Evaluation of Once-Weekly Islatravir and Lenacapavir for Chronic HIV-1 Management
Trial shows once-weekly pill may match daily HIV treatment
A Phase 3 trial demonstrates that a once-weekly islatravir-lenacapavir regimen maintains viral suppression comparable to daily standard-of-c…
A new once-weekly pill could offer a simpler way to manage HIV, showing similar success to daily pills in a recent clinical trial.
Aug 30, 2026
Infectious Disease
Meta-analysis
Doravirine and islatravir combination shows reduced virological failure risk in adults with HIV-1
Trial shows doravirine and islatravir reduce HIV-1 treatment failure
This meta-analysis evaluated the efficacy of a doravirine and islatravir regimen compared to standard triple option therapy for patients liv…
A new two-drug combination for HIV-1 shows a significantly lower risk of treatment failure compared to standard triple therapy.
Jun 25, 2026
Infectious Disease
Phase I
Islatravir and lenacapavir fixed-dose combination shows similar bioavailability to single agents in healthy volunteers
New HIV pill works with or without food in early safety tests
This open-label phase 1 study enrolled 93 people without HIV to assess the oral relative bioavailability and safety of a fixed-dose combinat…
A new HIV pill containing islatravir and lenacapavir showed similar drug levels whether taken with food or on an empty stomach, supporting f…
May 1, 2026
Allergy & Immunology
Phase III
Phase 3 trial compares switch to doravirine/islatravir versus continuing bictegravir/FTC/TAF in HIV-1
Phase 3 trial compares two HIV drug regimens for people already virologically suppressed
A phase 3 randomized controlled trial enrolled 643 virologically suppressed adults with HIV-1 to compare switching to doravirine/islatravir …
People with HIV already on effective treatment can safely switch to a new two-drug pill without losing virus control, according to a complet…
CT.gov
Apr 2, 2026